Abstract
Bone fractures and defects present significant challenges in orthopedic medicine, necessitating effective therapeutic strategies to expedite healing and restore skeletal function. Vanadium, a trace element with insulin-mimetic properties, has garnered attention for its potential role in enhancing bone healing. The concept of using local vanadium supplementation in the context of systemic diseases, such as diabetes mellitus, is not entirely new. Vanadium compounds, notably vanadyl acetylacetonate (VAC), have been recognized for their insulin-mimetic properties.1-5 In comparison to other orthobiologics like insulin and bone morphogenetic protein (BMP), vanadium compounds are highly stable, free from storage and contamination concerns, and can endure high elevated temperatures.6 This allows for the potential utilization of vanadium surface modification of orthopedic implants. Prior research, outlined in this review report, shows that the use of VAC can accelerate the rate of fracture healing in non-diabetic rats.7,8 This review synthesizes current literature on the mechanisms through which vanadium influences bone regeneration, focusing on preclinical studies utilizing a rat model. Key findings suggest that vanadium promotes osteoblast differentiation, inhibits osteoclast activity, and enhances biomechanical properties of healed bone. Controlled release systems for vanadium delivery may hold promise in optimizing its therapeutic efficacy. Dosing and controlled delivery can mitigate safety concerns while optimizing healing. Future research should aim to elucidate molecular mechanisms, explore synergistic effects with other bioactive agents, and conduct clinical trials to validate vanadium's efficacy and safety in human bone healing applications.